Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1201-1208

  Taatjes, Dylan J ^b   Koch, Tad H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

Daunoform; Daunorubicin; Doxoform; Doxorubicin; DU 145; Epidoxoform; Epidoxorubicin; Flow cytometry; Formaldehyde; LNCaP; MDR; Microscopy; PC 3

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FORMALDEHYDE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL NUCLEUS; CONJUGATE; CONTROLLED STUDY; COVALENT BOND; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DRUG CARRIERS; FLOW CYTOMETRY; FORMALDEHYDE; HUMANS; MALE; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0033023492     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Durand RE and Olive PL: Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 41: 3489-3494, 1981.
2. Mahler C and Denis L: Management of relapsing disease in prostate cancer. Cancer 70: 329-334, 1992.
3. Slack NH and Murphy GP: A decade of experience with chemotherapy for prostate cancer. Urology 22: 1-7, 1983.
4. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A and Mondillo S: Weekly chemotherapy in advanced prostatic cancer. BrJ Cancer 67: 1430-1436, 1993.
5. Kaighn ME, Narayan KS, Ohuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
6. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281, 1978.
7. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
8. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G and Hamilton G: Role of the mdr-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urology 150: 1544-1547, 1993.
9. Cullinane C, van Rosmalen A and Phillips DR: Does adriamycin induce interstrand cross-links in DNA? Biochemistry 33: 4632-4638, 1994.
10. Taatjes DJ, Gaudiano G, Resing K and Koch T: A redox pathway leading to the alkylation of DNA by the anthracycline, anti-tumor drugs, adrimaycin and daunomycin. J Med Chem 40: 1276-1286, 1997.
11. Wang AHJ, Gao YG, Liaw YC and Li Yk: Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 30: 3812-3815, 1991.
12. Taatjes DJ, Gaudiano G and Koch TH: Production of formaldehyde and DNA-adriamycin or-daunomycin adducts, initiated through redox chemistry of DTT/iron, xanthine oxidase/NADH/iron, or glutathione/iron. Chem Res Toxicol 10: 953-961, 1997.
13. Taatjes DJ, Fenick DJ and Koch TH: Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate, cytotoxic to resistant tumor cells. J Med Chem 41: 2452-2461, 1998.
14. Fenick DJ, Taatjes DJ and Koch TH: Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J Med Chem 40: 2452-2461, 1997.
15. van Rosmalen A, Cullinane C, Cutts SM and Phillips DR: Stability of adriamycin-induced DNA adducls and interstrand crosslinks. Nucleic Acids Res 23: 42-50, 1995.
16. Crooke ST and DuVernay VH Fluorescence quenching of anthracyclines by subcellular fractions. In: Crooke ST and Reich SD (eds.), Anthracyclines Current Status and New Developments, pp. 151-155. New York: Academic Press, 1980.
17. Roche CJ, Thomson JA and Crothers DM: Site selectivity of daunomycin. Biochemistry 33: 926-935, 1994.
18. Gallois L, Fiallo M, Laigle A, Priebe W and Garnier-Sullerot A: The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Eur J Biochem 241: 879-887, 1996.
19. Developmental Therapeutics Program NCI: Internet Address: http: //epnws1.ncifcrf.gov: 2345/dis3d/dtp.html.
20. Cullinane C and Phillips DR: The DNA sequence specificity of cyanomorpholinoadriamycin. FEBS Lett. 293: 195-198, 1991.
21. Cullinane C and Phillips DR: In vitro transcription analysis of DNA adducts induced by cyanomorpholinoadriamycin. Biochemistry 31: 9513-9519, 1992.
22. Cullinane C and Phillips DR: Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro. Nucleic Acids Res 27: 1857-1862, 1993.
23. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H and Priebe W: Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 36: 2679-2685, 1997.
24. Frezard F and Garnier-Suillerot A: Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J Biochem 196: 483-491, 1991.
25. Inouye S: On the prediction of pKa values of amino sugars. Chem Pharm Bull 16: 1134-1137, 1968.
26. Sinha BK and Mimnaugh EG: Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Rad Biol Med 8: 567-581, 1990.
27. Jung K, Seidel B, Rudolph B, Lein M, Cronauer MV, Henke W, Hampel G, Schnorr D and Loening SA: Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Rad Biol Med 23: 127-133, 1997.
28. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 supresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
29. Gudas JM, Nguyen H, Li T, Sadzewicz L, Robey R, Wosikowski K and Cowan KH: Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis 17: 1417-1427, 1996.
30. McConkey DJ, Greene G and Pettaway CA: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56: 5594-5599, 1996.